Print this page    •   Back to Web version of article

Medical News
Gilead Adds Discount, Price Freeze for AIDS Drugs

June 14, 2010

Gilead Sciences recently announced an extension of discounts and price freezes for several HIV drugs used by clients of AIDS drug assistance programs. Many state ADAPs continue to face budget shortfalls, and as of May there were 1,143 individuals on waiting lists for ADAP assistance, the drug maker noted in a statement issued jointly with the ADAP Crisis Task Force. Discounts and price freezes cover Truvada (emtricitabine and tenofovir), Viread (tenofovir), and Emtriva (emtricitabine) through December 31, 2013. In addition, Gilead said it is expanding its patient assistance program and eliminating minimum payments for patients in its co-pay assistance program. The ADAP Crisis Task Force was formed in 2002 by several state AIDS directors to respond to fiscal emergencies affecting ADAPs.

Back to other news for June 2010

Excerpted from:
Silicon Valley Business Journal

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.